Metin Figen
Metin Figen has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Esengul Kocak Uzel
Department of Radiation Oncology, Health Sciences University Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Bakirkoy-Istanbul, Turkey
6 shared publications - Meltem Kirli Bolukbas
Department of Radiation Oncology, Health Sciences University Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey
4 shared publications - Gülşen Pınar Soydemir
Department of Radiation Oncology, Health Sciences University Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Bakirkoy, Istanbul, Turkey
3 shared publications - Melisa Bagci
Department of Radiation Oncology, Marmara University Medical School, Istanbul, Turkey
2 shared publications - Adem Yilmaz
Department of Neurosurgery, Sisli Hamidiye Etfal Training and Research Hospital, University of Health Sciences, Istanbul, Turkey
1 shared publication - Ahmet Mesrur Halefoglu
Department of Radiology, Sisli Etfal Training and Research Hospital, Istanbul, Turkey
1 shared publication
Latest Publications
- Open Access
- 3 June 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Outcomes of hypofractionated stereotactic radiotherapy for brain metastases: do we treat patients or lesions?
- 3 June 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessOutcomes of hypofractionated stereotactic radiotherapy for brain metastases: do we treat patients or lesions?
- Open Access
- 16 February 2026
- Published by Springer Nature in Radiation Oncology
- Vol. 21 (1)
A practical non-custom abdominal corset-based approach for diaphragm motion management in stereotactic body radiotherapy
In Stereotactic body radiation therapy (SBRT), abdominal compression devices are commonly used to manage respiratory motion. The high cost, bulky design, a
- 16 February 2026
- Published by Springer Nature in Radiation Oncology
- Vol. 21 (1)
Open AccessA practical non-custom abdominal corset-based approach for diaphragm motion management in stereotactic body radiotherapy
In Stereotactic body radiation therapy (SBRT), abdominal compression devices are commonly used to manage respiratory motion. The high cost, bulky design, a
- Open Access
- 20 December 2024
- Published by Springer Nature in BMC Cancer
- Vol. 24 (1) , 1-8
Cancer awareness across borders: a comparative study of internet search trends for breast and prostate cancer in Europe and Turkey
The governments and private organizations strongly support cancer awareness campaigns. It remains unknown whether the campaigns during the awareness months have the same effect in every country. This study aims to compare the impact of awareness campaigns conducted in October for breast cancer and September for prostate cancer on internet search trends among the most populous European countries and Turkey. The research is framed within the context of comparing awareness campaign effects between countries for the first time. Utilizing Google Trends data from 2018 to 2022, we collected search term data for breast and prostate cancer in Germany, France, the United Kingdom, Italy, Spain, and Turkey. Search volumes were standardized based on each country’s population and internet user rates. Multivariate analysis of variance (MANOVA) was conducted to assess the influence of awareness campaigns on internet search volumes. The MANOVA results indicated that the awareness campaigns had a significant impact on internet search volumes for breast and prostate cancer. The campaigns were found to be statistically significant in Italy, France, United Kingdom for breast cancer. And also, the internet search volumes of Italy, France, and Germany increased statistically significant for prostate cancer. The internet search data of Turkey, Germany, France, the United Kingdom, Italy, and Spain were analyzed, revealing that both Italy and France responded positively to awareness campaigns for both breast and prostate cancer, resulting in increased awareness. These findings can serve as a guiding framework for developing effective strategies to enhance cancer awareness.
- 20 December 2024
- Published by Springer Nature in BMC Cancer
- Vol. 24 (1) , 1-8
Open AccessCancer awareness across borders: a comparative study of internet search trends for breast and prostate cancer in Europe and Turkey
The governments and private organizations strongly support cancer awareness campaigns. It remains unknown whether the campaigns during the awareness months have the same effect in every country. This study aims to compare the impact of awareness campaigns conducted in October for breast cancer and September for prostate cancer on internet search trends among the most populous European countries and Turkey. The research is framed within the context of comparing awareness campaign effects between countries for the first time. Utilizing Google Trends data from 2018 to 2022, we collected search term data for breast and prostate cancer in Germany, France, the United Kingdom, Italy, Spain, and Turkey. Search volumes were standardized based on each country’s population and internet user rates. Multivariate analysis of variance (MANOVA) was conducted to assess the influence of awareness campaigns on internet search volumes. The MANOVA results indicated that the awareness campaigns had a significant impact on internet search volumes for breast and prostate cancer. The campaigns were found to be statistically significant in Italy, France, United Kingdom for breast cancer. And also, the internet search volumes of Italy, France, and Germany increased statistically significant for prostate cancer. The internet search data of Turkey, Germany, France, the United Kingdom, Italy, and Spain were analyzed, revealing that both Italy and France responded positively to awareness campaigns for both breast and prostate cancer, resulting in increased awareness. These findings can serve as a guiding framework for developing effective strategies to enhance cancer awareness.
- 27 September 2022
- Published by Galenos Yayinevi in Medical Journal of Bakırkoy
- Vol. 18 (3) , 303-309
Can Temporal Muscle Thickness Be a New Prognostic Factor for De Novo Glioblastoma?
- 27 September 2022
- Published by Galenos Yayinevi in Medical Journal of Bakırkoy
- Vol. 18 (3) , 303-309
Can Temporal Muscle Thickness Be a New Prognostic Factor for De Novo Glioblastoma?
- Open Access
- 20 November 2021
- Published by Hindawi Limited in Case Reports in Oncological Medicine
- Vol. 2021, 1-14
Recurrent Solitary Fibrous Tumor in Intradural Extramedullary Space: Case Report and Review of the Literature
Solitary fibrous tumor/hemangiopericytoma (SFT/HPC) is a rare neoplasm arising from spindle cells and most commonly arising from pleura. Spinal SFT/HPC is a rare entity; hence, it is not on the top of the differential diagnosis list when a clinician faces a spinal lesion. In the review of the literature, there exist less than 50 case reports of intradural extramedullary SFT/HPC. Here, we present a 54-year-old female patient who underwent subtotal surgical excision of an intradural extramedullary spinal mass pathologically reported to be SFT/HPC and had symptomatic recurrence in the 3(rd) year of follow-up. Surgical intervention was unachievable and the patient was given 45 Gy to the surgical cavity followed by a 5.4 Gy boost to visible tumor with external radiotherapy. Patient reported significant relief of her symptoms. We aim to contribute to the formation of a treatment algorithm for this rare entity.
- 20 November 2021
- Published by Hindawi Limited in Case Reports in Oncological Medicine
- Vol. 2021, 1-14
Open AccessRecurrent Solitary Fibrous Tumor in Intradural Extramedullary Space: Case Report and Review of the Literature
Solitary fibrous tumor/hemangiopericytoma (SFT/HPC) is a rare neoplasm arising from spindle cells and most commonly arising from pleura. Spinal SFT/HPC is a rare entity; hence, it is not on the top of the differential diagnosis list when a clinician faces a spinal lesion. In the review of the literature, there exist less than 50 case reports of intradural extramedullary SFT/HPC. Here, we present a 54-year-old female patient who underwent subtotal surgical excision of an intradural extramedullary spinal mass pathologically reported to be SFT/HPC and had symptomatic recurrence in the 3(rd) year of follow-up. Surgical intervention was unachievable and the patient was given 45 Gy to the surgical cavity followed by a 5.4 Gy boost to visible tumor with external radiotherapy. Patient reported significant relief of her symptoms. We aim to contribute to the formation of a treatment algorithm for this rare entity.
- Open Access
- 12 November 2020
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 10
Radiotherapy for Head and Neck Cancer: Evaluation of Triggered Adaptive Replanning in Routine Practice
Purpose and Objective: A proportion of patients receiving radiotherapy for head and neck squamous cell carcinoma (HNSCC) require ad hoc treatment re-planning. The aim of this retrospective study is to analyze the patients who required ad hoc re-planning and to identify factors, which may predict need for re-planning. Materials and Methods: A single center evaluation of all patients receiving radical or adjuvant (chemo)radiotherapy (CRT) for HNSCC between January and December 2016 was undertaken. Patients who underwent ad hoc re-planning during the treatment were identified in electronic records. Reasons for re-planning were categorized as: weight loss, tumor shrinkage, changes in patient position and immobilization-related factors. Potential trigger factors for adaptive radiotherapy such as patient characteristics, primary tumor site, stage, concomitant chemotherapy, weight loss ratios, radical/adjuvant treatment, and nutritional interventions were investigated. Results: 31/290 (10.6%) HNSCC patients who underwent radical/adjuvant radiotherapy required re-planning. The adaptive radiotherapy (ART) was performed at a mean fraction of 15. The most common documented reasons for re-planning were tumor shrinkage (35.5%) and weight loss (35.5%). Among the patient/tumor/treatment factors, nasopharyngeal primary site (p = 0.013) and use of concurrent chemotherapy with radiotherapy (p = 0.034) were found to be significantly correlated with the need for re-planning. Conclusion: Effective on-treatment verification schedules and close follow up of patients especially with NPC primary and/or treated with concurrent chemoradiotherapy are crucial to identify patients requiring ART. We suggest an individualized triggered approach to ART rather than scheduled strategies as it is likely to be more feasible in terms of utilization of workload and resources.
- 12 November 2020
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 10
Open AccessRadiotherapy for Head and Neck Cancer: Evaluation of Triggered Adaptive Replanning in Routine Practice
Purpose and Objective: A proportion of patients receiving radiotherapy for head and neck squamous cell carcinoma (HNSCC) require ad hoc treatment re-planning. The aim of this retrospective study is to analyze the patients who required ad hoc re-planning and to identify factors, which may predict need for re-planning. Materials and Methods: A single center evaluation of all patients receiving radical or adjuvant (chemo)radiotherapy (CRT) for HNSCC between January and December 2016 was undertaken. Patients who underwent ad hoc re-planning during the treatment were identified in electronic records. Reasons for re-planning were categorized as: weight loss, tumor shrinkage, changes in patient position and immobilization-related factors. Potential trigger factors for adaptive radiotherapy such as patient characteristics, primary tumor site, stage, concomitant chemotherapy, weight loss ratios, radical/adjuvant treatment, and nutritional interventions were investigated. Results: 31/290 (10.6%) HNSCC patients who underwent radical/adjuvant radiotherapy required re-planning. The adaptive radiotherapy (ART) was performed at a mean fraction of 15. The most common documented reasons for re-planning were tumor shrinkage (35.5%) and weight loss (35.5%). Among the patient/tumor/treatment factors, nasopharyngeal primary site (p = 0.013) and use of concurrent chemotherapy with radiotherapy (p = 0.034) were found to be significantly correlated with the need for re-planning. Conclusion: Effective on-treatment verification schedules and close follow up of patients especially with NPC primary and/or treated with concurrent chemoradiotherapy are crucial to identify patients requiring ART. We suggest an individualized triggered approach to ART rather than scheduled strategies as it is likely to be more feasible in terms of utilization of workload and resources.
- Open Access
- 14 March 2013
- Published by Hindawi Limited in Case Reports in Oncological Medicine
- Vol. 2013, 1-4
Malignant Fibrous Histiocytoma of the Breast in Young Male Patient: A Case Report and a Review of the Literature
Malignant Fibrous Histiocytoma (MFH) is a fairly common tumor in the deep soft tissues: the most frequent primary sites are the lower (49%) and upper (19%) limbs, but it has been reported even in the retroperitoneum and abdomen (16%), while localization in the breast is extremely rare (1-2). Breast cancer is rarely seen in males, accounts for approximately 1% of all breast cancer, and the breast sarcomas constitute less than 1% of breast tumors in both sexes. In the review of the literature, this is the third male and first young male with MFH. Here, we present a 37-years-old male patient who is diagnosed to have malignant fibrous histiocytoma in a variant of pleomorphic fusiform cell localized in the left breast. Following the wide local excision, the patient was given an adjuvant 50 Gy of external radiotherapy. He remained alive and well after 42 months of followup. We believe that reporting such few cases would contribute to forming treatment algorithms of rare tumors.
- 14 March 2013
- Published by Hindawi Limited in Case Reports in Oncological Medicine
- Vol. 2013, 1-4
Open AccessMalignant Fibrous Histiocytoma of the Breast in Young Male Patient: A Case Report and a Review of the Literature
Malignant Fibrous Histiocytoma (MFH) is a fairly common tumor in the deep soft tissues: the most frequent primary sites are the lower (49%) and upper (19%) limbs, but it has been reported even in the retroperitoneum and abdomen (16%), while localization in the breast is extremely rare (1-2). Breast cancer is rarely seen in males, accounts for approximately 1% of all breast cancer, and the breast sarcomas constitute less than 1% of breast tumors in both sexes. In the review of the literature, this is the third male and first young male with MFH. Here, we present a 37-years-old male patient who is diagnosed to have malignant fibrous histiocytoma in a variant of pleomorphic fusiform cell localized in the left breast. Following the wide local excision, the patient was given an adjuvant 50 Gy of external radiotherapy. He remained alive and well after 42 months of followup. We believe that reporting such few cases would contribute to forming treatment algorithms of rare tumors.